Ajanta Pharma has informed that the Company’s Paithan facility was recently inspected by US FDA and the Company has issued one procedural related 483. The Company is in process of responding to the same within the stipulated time prescribed by US FDA.
The above information is a part of company’s filings submitted to BSE.